Last reviewed · How we verify
illuccix 68Ga-PSMA-11 Total Body PET-CT
illuccix 68Ga-PSMA-11 Total Body PET-CT is a Small molecule drug developed by BAMF Health. It is currently in Phase 1 development.
At a glance
| Generic name | illuccix 68Ga-PSMA-11 Total Body PET-CT |
|---|---|
| Sponsor | BAMF Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Total Body PET-CT Imaging of Prostate Cancer Using Illuccix (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- illuccix 68Ga-PSMA-11 Total Body PET-CT CI brief — competitive landscape report
- illuccix 68Ga-PSMA-11 Total Body PET-CT updates RSS · CI watch RSS
- BAMF Health portfolio CI
Frequently asked questions about illuccix 68Ga-PSMA-11 Total Body PET-CT
What is illuccix 68Ga-PSMA-11 Total Body PET-CT?
illuccix 68Ga-PSMA-11 Total Body PET-CT is a Small molecule drug developed by BAMF Health.
Who makes illuccix 68Ga-PSMA-11 Total Body PET-CT?
illuccix 68Ga-PSMA-11 Total Body PET-CT is developed by BAMF Health (see full BAMF Health pipeline at /company/bamf-health).
What development phase is illuccix 68Ga-PSMA-11 Total Body PET-CT in?
illuccix 68Ga-PSMA-11 Total Body PET-CT is in Phase 1.